ArticleEndocrine connections2026
Association of GnRH agonists with depression and suicide/self-injury: a FAERS pharmacovigilance study.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between gonadotropin-releasing hormone agonists (GnRH-as) and depression and suicide/self-injury (DASSI) remains controversial. This study aimed to investigate this potential association using data from the FDA Adverse Event Reporting System (FAERS) database. Methods: Instances of DASSI linked with GnRH-as were identified from FAERS (2004Q1 to 2024Q1). Time-to-onset (TTO) analyses and disproportionality analysis (DPA) were employed to assess onset timing and signal values for adverse events. The influence of concurrent medications on DASSI was evaluated using the Ω shrinkage measure. Results: A total of 5,454 DASSI cases linked to GnRH-as were identified. TTO analyses showed earlier onset of DASSI in females, children (<18), and adults (18-65) compared to males and elders (>65) (females vs males: 3.5 (0.5-29.5) vs 120.5 (0.5-441.5) days, P < 0.001; children vs elders: 10.5 (0.5-78.5) vs 129.5 (0.5-490.5) days, P < 0.001; adults vs elders: 7.0 (0.5-81.0) vs 129.5 (0.5-490.5) days, P < 0.001). DPA revealed stronger signals for depression and suicide/self-injury in females and oncology patients compared to males and non-oncology patients. Co-medication analysis identified depressive interactions with multiple drug combinations. Conclusions: Although causality cannot be inferred from FAERS data and the results should be interpreted cautiously, we identified some signals of disproportionate reporting of DASSI for certain GnRH-a therapies. These hypothesis-generating findings may raise clinical awareness and inform a risk-informed monitoring framework (e.g., baseline assessment of mood and suicidality, patient/caregiver education on warning signs, and early follow-up) but require confirmation in well-designed epidemiologic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.